Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.67 |
| ▸ | KLK6 | Q92876 | 1/20 | 0.67 |
| ▸ | F2 | P00734 | 5/20 | 0.65 |
| ▸ | PLG | P00747 | 2/20 | 0.64 |
| ▸ | PROC | P04070 | 2/20 | 0.64 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.64 |
| ▸ | PLAT | P00750 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7220112 | 1.00 | F10 (0.67) | F10KLK6F2PLGPROC | |
| SCHEMBL14603144 | 0.85 | F10 (0.79) | F10KLK6 | |
| SCHEMBL7538352 | 0.85 | F10 (0.59) | F10KLK6F2PLGPROC | |
| SCHEMBL7214106 | 0.81 | F10 (0.58) | F10KLK6F2PLGPROC | |
| SCHEMBL7214103 | 0.81 | F10 (0.58) | F10KLK6F2PLGPROC | |
| SCHEMBL14603272 | 0.81 | F10 (0.61) | F10KLK6F2 | |
| SCHEMBL7543784 | 0.81 | F10 (0.75) | F10F2PLGPROCPRSS1 | |
| SCHEMBL2325171 | 0.80 | F10 (0.74) | F10KLK6F2PLGPROC | |
| SCHEMBL2329405 | 0.80 | F10 (0.73) | F10KLK6F2PLGPROC | |
| Trifluoroacetic Acid SCHEMBL2329078 | 0.79 | F10 (0.71) | F10KLK6F2PLGPROC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6602864-B1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-08-05 | — | — | US | disclosed |
| EP-0944386-B1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARMA INC (US) | 2002-09-18 | — | — | EP | disclosed |
| US-20020013310-A1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2002-01-31 | — | — | US | disclosed |
| US-6281227-B1 | INHIBITORS OF THE ACTIVITY OF FACTOR XA. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013310-A1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | STS, ARSA, F12 | F10 20/4885KLK6 954/4885F2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.